Evidence map›Paper›PMID 32370165›Full record

ArticleNanomaterials (Basel, Switzerland)2020

XPS Modeling of Immobilized Recombinant Angiogenin and Apoliprotein A1 on Biodegradable Nanofibers.

Anton Manakhov, Elizaveta Permyakova, Sergey Ershov, Svetlana Miroshnichenko, Mariya Pykhtina, Anatoly Beklemishev, Andrey Kovalskii, Anastasiya Solovieva

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Anton ManakhovResearch Institute of Clinical and Experimental Lymphology-Branch of the ICG SB RAS, 2 Timakova str., 630060 Novosibirsk, Russia.ORCID 0000-0003-4517-1682
Elizaveta PermyakovaResearch Institute of Clinical and Experimental Lymphology-Branch of the ICG SB RAS, 2 Timakova str., 630060 Novosibirsk, Russia.ORCID 0000-0003-2581-0803
Sergey ErshovLaboratory for the Physics of Advanced Materials (LPM), Department of Physics and Materials Science, University of Luxembourg, L-1511 Luxembourg, Luxembourg.
Svetlana MiroshnichenkoResearch Institute of Clinical and Experimental Lymphology-Branch of the ICG SB RAS, 2 Timakova str., 630060 Novosibirsk, Russia.
Mariya PykhtinaResearch Institute of Clinical and Experimental Lymphology-Branch of the ICG SB RAS, 2 Timakova str., 630060 Novosibirsk, Russia.
Anatoly BeklemishevResearch Institute of Clinical and Experimental Lymphology-Branch of the ICG SB RAS, 2 Timakova str., 630060 Novosibirsk, Russia.ORCID 0000-0001-9732-1246
Andrey KovalskiiNational University of Science and Technology "MISiS", Leninsky pr. 4, Moscow 119049, Russia.
Anastasiya SolovievaResearch Institute of Clinical and Experimental Lymphology-Branch of the ICG SB RAS, 2 Timakova str., 630060 Novosibirsk, Russia.ORCID 0000-0002-7740-8456
Siberian Branch of the Russian Academy of Sciences · RUNational University of Science and Technology · RUUniversity of Luxembourg · LU

Funding

Russian Science Foundation 18-75-10057
6 · The paper itself

Abstract

The immobilization of viable proteins is an important step in engineering efficient scaffolds for regenerative medicine. For example, angiogenin, a vascular growth factor, can be considered a neurotrophic factor, influencing the neurogenesis, viability, and migration of neurons. Angiogenin shows an exceptional combination of angiogenic, neurotrophic, neuroprotective, antibacterial, and antioxidant activities. Therefore, this protein is a promising molecule that can be immobilized on carriers used for tissue engineering, particularly for diseases that are complicated by neurotrophic and vascular disorders. Another highly important and viable protein is apoliprotein A1. Nevertheless, the immobilization of these proteins onto promising biodegradable nanofibers has not been tested before. In this work, we carefully studied the immobilization of human recombinant angiogenin and apoliprotein A1 onto plasma-coated nanofibers. We developed a new methodology for the quantification of the protein density of these proteins using X-ray photoelectron spectroscopy (XPS) and modeled the XPS data for angiogenin and apoliprotein A1 (Apo-A1). These findings were also confirmed by the analysis of immobilized Apo-A1 using fluorescent microscopy. The presented methodology was validated by the analysis of fibronectin on the surface of plasma-coated poly(ε-caprolactone) (PCL) nanofibers. This methodology can be expanded for other proteins and it should help to quantify the density of proteins on surfaces using routine XPS data treatment.

Indexed as

angiogeninbiotechnologynanofibersplasmapolymersX-ray photoelectron spectroscopy

Identifiers

PMID32370165
PMCPMC7279301
OpenAlexW3022804789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.